AXIS Medical Education

Episodes 1-4 of 4

• 

  RestartResume

  ADCs Across the Spectrum of HER2 Expression in Metastatic Breast Cancer

  RestartResume

  ADCs Across the Spectrum of HER2 Expression in Metastatic Breast Cancer

  CME/CE

  ADCs Across the Spectrum of HER2 Expression in Metastatic Breast Cancer

  0.25 credits

  • 

    

    Reshma L. Mahtani, DO

  0.25 credits

• 

  RestartResume

  Chairperson's Perspective: Novel Treatments for Newly Diagnosed Ph+ CML-CP: Striking the Balance of Treatment With Patient Goals and QoL

  RestartResume

  Chairperson's Perspective: Novel Treatments for Newly Diagnosed Ph+ CML-CP: Striking the Balance of Treatment With Patient Goals and QoL

  CME/CE

  Chairperson's Perspective: Novel Treatments for Newly Diagnosed Ph+ CML-CP: Striking the Balance of Treatment With Patient Goals and QoL

  0.25 credits

  • 

    

    Jorge E. Cortes, MD

  0.25 credits

• 

  RestartResume

  Advancing ALK Inhibition Into Early-Stage NSCLC: Integrating Biomarker-Driven Therapies to Reduce Recurrence Risk Post Resection

  RestartResume

  Advancing ALK Inhibition Into Early-Stage NSCLC: Integrating Biomarker-Driven Therapies to Reduce Recurrence Risk Post Resection

  CME/CE

  Advancing ALK Inhibition Into Early-Stage NSCLC: Integrating Biomarker-Driven Therapies to Reduce Recurrence Risk Post Resection

  0.25 credits

  • 

    

    Mark Socinski, MD

  0.25 credits

• 

  RestartResume

  Chairperson's Perspective: Redefining Treatment Across the Spectrum of HR+/HER2-Expressing Metastatic Breast Cancer

  RestartResume

  Chairperson's Perspective: Redefining Treatment Across the Spectrum of HR+/HER2-Expressing Metastatic Breast Cancer

  CME/CE

  Chairperson's Perspective: Redefining Treatment Across the Spectrum of HR+/HER2-Expressing Metastatic Breast Cancer

  0.25 credits

  • 

    

    Sara M. Tolaney, MD, MPH

  0.25 credits